Premium
New agents in acute myeloid leukemia and other myeloid disorders
Author(s) -
Ravandi Farhad,
Kantarjian Hagop,
Giles Francis,
Cortes Jorge
Publication year - 2004
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11935
Subject(s) - myeloid leukemia , medicine , acute promyelocytic leukemia , imatinib mesylate , leukemia , imatinib , drug , cancer , myeloid , retinoic acid , immunology , pharmacology , biology , biochemistry , gene
Over the past several decades, improvements in chemotherapeutic agents and supportive care have resulted in significant progress in treating patients with acute myeloid leukemia (AML). More recently, advances in understanding the biology of AML have resulted in the identification of new therapeutic targets. The success of all‐trans‐retinoic acid in acute promyelocytic leukemia and of imatinib mesylate in chronic myeloid leukemia have demonstrated that targeted therapy may be more effective and less toxic when well defined targets are available. At the same time, understanding mechanisms of drug resistance and means to overcome them has led to modification of some of the existing cytotoxic agents. Rational design and conduct of clinical trials is necessary to ensure that the full potential of these new agents is realized. Cancer 2004. © 2003 American Cancer Society.